Director / Senior Director of Strategic Pricing, Government Pricing, and GPO
 AVEO Pharmaceuticals | |
 United States, Massachusetts, Boston | |
| 30 Winter Street (Show on map) | |
 Sep 17, 2025 | |
|
Position: Director / Senior Director of Strategic Pricing, Government Pricing, and GPO Department: Market Access Reports to: Senior Vice President, Market Access & Alliance Management Location: Hybrid (Boston Seaport Office) Job Summary: The Director / Senior Director of Strategic Pricing, Government Pricing, and GPO will serve as a key leader within the Commercial organization, responsible for developing and executing pricing strategies for our existing and pipeline products. The role will be tasked with maximizing patient access and net revenue, managing gross-to-net (GTN) inclusive of forecasts and liabilities, ensuring compliance with federal and state regulations-including Inflation Reduction Act (IRA) rebate reporting-and optimizing performance across Group Purchasing Organization (GPO) channels. This role requires deep expertise in government program pricing, GTN management, strategic pricing analytics, and commercial contracting with a focus on driving sustainable value creation for the business while ensuring robust patient access. Key Responsibilities: Strategic Pricing & Contracting * Lead development and implementation of pricing strategies, balancing patient access, payer dynamics, and company financial objectives * Evaluate competitive pricing & market dynamics to inform strategic decision-making * Partner with Market Access, Finance, and Marketing personnel to align pricing strategies with business objectives and product lifecycle plans * Oversee commercial contracting strategy and execution for GPOs and key institutional customers, ensuring accurate price loading in the marketplace * Lead the presentation of pricing committee recommendations Government Pricing & Compliance * Direct all aspects of government price reporting in compliance with Medicaid, Medicare, PHS/340B, Tricare, and VA requirements * Oversee development, management and validation of government pricing calculations, ensuring timely and accurate submission to CMS and other agencies * Lead compliance and reporting requirements associated with the Inflation Reduction Act (IRA), including Medicare Part D and Part B rebate liability calculations, data validation, and financial impact assessments * Partner with Legal, Compliance, and Regulatory teams to maintain robust policies and controls, ensuring adherence to federal and state pricing requirements Gross-to-Net (GTN) Management * Lead development and oversight of GTN forecasts and accruals, ensuring accurate reflection of rebates, chargebacks, admin fees, copay support, and government liabilities * Partner with Finance, Accounting, and Market Access personnel to monitor GTN performance, reconcile actuals vs. forecasts, and explain key drivers of variance * Provide strategic insights to senior leadership on GTN trends, risks, and opportunities, including the impact of pricing strategies, payer dynamics, and IRA rebate exposure to long-term profitability GPO & Channel Strategy * Collaborate with GPO team in the assessment and evolution of the GPO contracting strategy, including baseline analytics and rebate structure recommendations across aggregated and non-aggregated accounts * Partner with National Accounts and Trade/Distribution teams to optimize channel mix, access, and customer engagement (as appropriate) * Develop performance metrics and dashboards to monitor GPO contract compliance, rebate utilization, and ROI on channel investments Cross-Functional Collaboration * Collaborate closely with Market Access, Sales, Finance, Legal, and Compliance to ensure alignment on pricing, contracting, and reporting strategies * Provide executive-level insights and recommendations to senior leadership on pricing trends, risks, and opportunities * Partner with Sales Operations in managing data aggregator to ensure Market Access data integrity * Support Trade & Distribution in ensuring SAP data responsibilities are fulfilled Qualifications:
AVEO Oncology ("AVEO") is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients lives. On January 20, 2023, AVEO was acquired by LG Chem, Ltd. ("LG Chem"), establishing a U.S. commercial presence for LG Chem and expanding LG Chem's global oncology portfolio. AVEO continues to commercialize FOTIVDA (tivozanib) in the U.S. To learn more about FOTIVDA efficacy, safety, and relevant resources, visit FOTIVDAHCP.com. | |